Alliance Pharma PLC Notification of Major Interest in Shares (6019Q)
November 30 2016 - 11:00AM
UK Regulatory
TIDMAPH
RNS Number : 6019Q
Alliance Pharma PLC
30 November 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
----------------------------------------------------------------------------------------------------------------
1. Identity of the issuer or Alliance Pharma plc
the underlying issuer
of existing shares to which
voting rights are
attached:
--------------------------------------------------------------- -----------------------------------------------
2 Reason for the notification (please tick the appropriate
box or boxes):
----------------------------------------------------------------------------------------------------------------
An acquisition or disposal of voting rights
--------------------------------------------------------------------------------------------------------------
An acquisition or disposal of qualifying financial
instruments which may result in the acquisition
of shares already issued to which voting rights
are attached
--------------------------------------------------------------------------------------------------------------
An acquisition or disposal of instruments with
similar economic effect to qualifying financial
instruments
--------------------------------------------------------------------------------------------------------------
An event changing the breakdown of voting rights
--------------------------------------------------------------------------------------------------------------
Other (please CHANGE IN NATURE : RETURN OF LOANED SHARES
specify):
----------------------------------------------------------- -------------------------------------------------
3. Full name of person(s) Aviva plc & its subsidiaries
subject to the
notification obligation:
------------------------------------------------------------- -------------------------------------------------
4. Full name of shareholder(s) Registered Holder:
(if different from 3.):
Available on request 18,450*
BNY Norwich Union Nominees
Limited 2,744,814*
Chase (GA Group) Nominees
Limited 39,988,304*
*denotes direct interest
Chase Nominees Limited 1,382,120
------------------------------------------------------------- -------------------------------------------------
5. Date of the transaction 29 November 2016
and date on
which the threshold is
crossed or
reached:
------------------------------------------------------------- -------------------------------------------------
6. Date on which issuer 30 November 2016
notified:
------------------------------------------------------------- -------------------------------------------------
7. Threshold(s) that is/are 8% to 9% Change at Direct
crossed or Interest Level (Box 8A)
reached:
------------------------------------------------------------- -------------------------------------------------
8. Notified details:
--------------------------------------------------------------------------------------------------------------
A: Voting rights attached to shares
--------------------------------------------------------------------------------------------------------------
Class/type Situation previous Resulting situation after the
of to the triggering triggering transaction
shares transaction
if possible
using
the ISIN
CODE
---------------- ------------------------------ ------------------------------------------------------------
Number Number Number Number of voting % of voting
of of of shares rights rights
Shares Voting
Rights
---------------- ---------------- ------------ ------------- ------------------------ -------------------
Direct Direct Indirect Direct Indirect
---------------- ---------------- ------------ ------------- ----------- ----------- ------- ----------
Ordinary
Shares
GB0031030819 44,241,981* 44,241,981* 44,133,688 42,751,568 1,382,120 9.06% 0.29%
---------------- ------------ ------------- ----------- ----------- ------- ----------
* Includes Right to Recall Loaned Shares (1,132,875)
--------------------------------------------------------------------------------------------------------------
B: Qualifying Financial Instruments
--------------------------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
--------------------------------------------------------------------------------------------------------------
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion rights that rights
instrument Period may be
acquired if
the
instrument
is
exercised/
converted.
---------------- ---------------- --------------------------- ------------------------ -------------------
108,293*
RIGHT TO RECALL
LOANED SHARES N/A N/A *Direct Interest 0.02%
---------------- ---------------- --------------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
-----------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
-----------------------------------------------------------------------------------------------
Type of financial Exercise Expiration Exercise/ Number of voting % of voting
instrument price date Conversion rights instrument rights
period refers to
------------------ --------- ----------- ------------ ------------------- ----------------
Nominal Delta
------------------ --------- ----------- ------------ ------------------- -------- ------
Total (A+B+C)
------------------------------------------------------
Number of voting rights Percentage of voting rights
------------------------ ----------------------------
44,241,981 9.37%
------------------------ ----------------------------
9. Chain of controlled undertakings through which the
voting rights and/or the
financial instruments are effectively held, if applicable:
--------------------------------------------------------------------------------------------
The voting rights are managed and controlled by Aviva
Investors Global Services Limited and Friends Provident
International Limited, with the following chain of controlled
undertakings:-
Aviva Investors Global Services Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Investors Holdings Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Aviva Investors Global Services Limited (wholly owned
subsidiary of Aviva Investors Holdings Limited)
Friends Provident International Limited:
* Aviva plc (Parent Company)
* Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc)
* Aviva Life Holdings UK Limited (wholly owned
subsidiary of Aviva Group Holdings Limited)
* Friends Life FPG Limited (wholly owned subsidiary of
Aviva Life Holdings UK Limited)
* Friends Life FPL Limited (wholly owned subsidiary of
Friends Life FPG Limited)
* Friends Life Limited (wholly owned subsidiary of
Friends Life FPL Limited)
* Friends Life and Pensions Limited (wholly owned
subsidiary of Friends Life Limited)
* Friends Provident International Limited (wholly owned
subsidiary of Friends Life and Pensions Limited)
Proxy Voting:
--------------------------------------------------------------------------------------------
10. Name of the proxy holder: See Section 4
-------------------------------------------------- ----------------------------------------
11. Number of voting rights proxy
holder will cease
to hold:
-------------------------------------------------- ----------------------------------------
12. Date on which proxy holder will
cease to hold
voting rights:
-------------------------------------------------- ----------------------------------------
13. Additional information: Figures are based on a total
number of voting rights of
471,983,986, as per the Company's
Exercise of Share Options announcement
of 23(rd) November 2016.
-------------------------------------------------- ----------------------------------------
14. Contact name: Neil Whittaker, Aviva plc
-------------------------------------------------- ----------------------------------------
15. Contact telephone number: 01603 684420
-------------------------------------------------- ----------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLEASFEDSLKFFF
(END) Dow Jones Newswires
November 30, 2016 11:00 ET (16:00 GMT)
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alliance Pharma (LSE:APH)
Historical Stock Chart
From Apr 2023 to Apr 2024
